Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the…
- Trial name
- NCT00673140
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength), Far infrared radiation
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- GAAD Medical Research Institute Inc.
Amyotrophic Lateral Sclerosis (ALS)
A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV
This is a prospective, open-label, follow up study to protocol 101/2 - continued treatment by IPL344 IV administered once a day in up to 15 participants with ALS.
- Trial name
- NCT03755167
- Testing
- IPL344
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Immunity Pharma Ltd.
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange
The median survival of patients with amyotrophic lateral sclerosis (ALS) is 3 to 5 years and mortality is mainly related to respiratory failure.
- Trial name
- ANEX (NCT05837507)
- Testing
- Telerehabilitation solution (m-Rehab), Usual management including NIV.
- Where
- 2 sites in France
- Volunteers
- 43 people
- Sponsor
- University Hospital, Montpellier
ALS (Amyotrophic Lateral Sclerosis)
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
The goal of this clinical trial is to learn if drug CB03-154 works to treat ALS in adults. It will also learn about the safety of drug CB03-154.
- Trial name
- NCT07082192
- Testing
- Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg group
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Tetraplegia, Functional Tetraplegia
Study of Home Use of the Jaco Robotic Manipulation Device by Individuals With Tetraplegia
For all individuals deprived of active and functional motor control of the upper limbs to perform grasping tasks, the restoration of a grasping function becomes a priority.
- Conditions
- Tetraplegia, Functional Tetraplegia, Spinal Cord Injury, Muscular Dystrophy
- Trial name
- TETRAJACO (NCT07680361)
- Testing
- Use of the JACO robotic arm for a period of 2 months
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Association APPROCHE
Amyotrophic Lateral Sclerosis
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to 1) to receive by mouth seven morning doses of CC100 or placebo for 7 days.
- Trial name
- CC100B (NCT03049046)
- Testing
- CC100
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Chemigen, LLC
Amyotrophic Lateral Sclerosis, Renal Insufficiency
Dexpramipexole Renal PK Study
This is a multicenter, open-label, single-dose, PK and safety study in subjects with various stages of renal impairment.
- Trial name
- NCT01424176
- Testing
- Dexpramipexole (dose 1), Dexpramipexole (dose 2)
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Knopp Biosciences
Frontotemporal Lobar Degeneration, Amyotrophic Lateral Sclerosis
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)
The project focuses on C9orf72, the most frequent genetic form of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD) and amyotrophic lateral sclerosis (ALS).
- Trial name
- PREV-DEMALS (NCT02590276)
- Testing
- characterization
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Failure
Respiratory Care in Intensive Care Unit for Neuromuscular Patients
Retrospective multicentric observational study exploring the population of adult neuromuscular patients presenting a respiratory distress requiring their admission in an Intensive Care Unit (ICU) for ventilatory support.
- Trial name
- NCT02936908
- Testing
- Ventilatory support
- Where
- 4 sites in France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
ALS
Remote Pulmonary Function Testing and Nurse Coaching in ALS
Comparison of respiratory outcomes in patients receiving telemedicine-guided remote pulmonary function testing (rPFT) with or without the additional support of nurse coaching.
- Trial name
- NCT04490148
- Testing
- remote pulmonary function testing, standard pulmonary function testing, Nurse Respiratory Health Coaching (NRHC)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Milton S. Hershey Medical Center
ALS
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.
- Trial name
- NCT05568615
- Testing
- MT-1186
- Where
- 11 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Shionogi
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene.
- Trial name
- NCT02686268
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 128 people
- Sponsor
- Washington University School of Medicine
Spinal Cord Injury, Amyotrophic Lateral Sclerosis
iBCI Optimization for Veterans With Paralysis
VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis…
- Conditions
- Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome
- Trial name
- NCT05470478
- Testing
- Mobile neural decoding platform (mobile iBCI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- VA Office of Research and Development
Amyotrophic Lateral Sclerosis (ALS)
Study of COYA 302 for the Treatment of ALS
The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- ALSTARS (NCT07161999)
- Testing
- COYA 302
- Where
- 25 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Coya Therapeutics
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
Muscular Biomarkers in Amyotrophic Lateral Sclerosis
The first objective is to find some biomarkers, or a profile of biomarkers of ALS to help to diagnosis. The second objective is to better understand the pathogenesis of this disease by the exploration of muscle, blood and…
- Trial name
- METABOMU (NCT02670226)
- Testing
- Samples
- Where
- 2 sites in France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
Intermuscular Coherence as a Biomarker for ALS
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS.
- Trial name
- ALS-IMC (NCT05104710)
- Where
- 4 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Amyotrophic Lateral Sclerosis
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
- Trial name
- NCT06069934
- Testing
- Pridopidine
- Where
- 32 sites in United States, Puerto Rico
- Sponsor
- Prilenia
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) is a rare clinical entity, in which both disorders are variably associated in the same patient or within the family.
- Trial name
- NCT00159198
- Where
- 15 sites in France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Background: Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). The mutation causes a small piece of DNA to repeat itself thousands of times.
- Trial name
- NCT01925196
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)